AT - Platinum Compounds Flashcards

1
Q

Platinum based drugs are __________ complexes of platinum.

A

Coordination

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is the main dose-limiting side effect of cancer treatment with platinum compounds?

A

Neurotoxicity, whic causes peripheral neuropathies including polyneuropathy.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Platinum drugs act mostl on the adjacent N-_ position of ______, forming a 1,2 intrastrand crosslink. What does the resulting crosslinking cause?

A

N-7 of guanine.

Causes inhibition of DNA repair and/or DNA synthesis in cancer cells.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Platinum drugs cause crosslinking of DNA as:

A

Monoadducts
Interstrand crosslinks
Intrastand crosslinks
DNA protein crosslinks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is the structure of a platinum based drug we need to know for exam?

A

Platinum has 4 attached atoms/moietys.

Two NH3 on the left.
One Cl top right.
One H2O+ on bottom right.

Binds to the guanine N7 position.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

The loss of what receptor leads to less platinum entering cells, and consequently, drug resistance?

A

CTR1.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Once inside the cell, cisplatin is activated how?

A

The addition of water molecules to form a chemically reactive aqua species. This is facilitated by the relatively low chloride concentrations that are found within cells.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

The conversion of cisplatin to its activated form, via addition of water molecules, is facilitated by what?

A

The relatively low chloride concentrations that are found within cells.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

When in the cytoplasm, why does the activated aqua species of cisplatinum preferentially react with those cellular contents which have many cysteine or methionine amino acids?

A

They are high in sulphur.

Tripeptide glutathione and metallothioneins.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Levels of glutathione and metallothionein are relatively high in some platinum-resistant cancer cells, why does this cause resistance?

A

Mops up the platinum in the cytoplasm before the platinum can enter the nucleus and bind to the DNA.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Active export of platinum based chemotherapies from the cell can occur via

A

Copper exporters ATP7A and ATP7B.

Glutathione S-conjugate export GS-X pump.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What are the three ways that tumour resistance to cisplatin and carboplatin can occur?

A

(1) Loss of CTR1 - a mechanism by which they enter the cell = less platinum in cell.
(2) Elevated levels of glutathionine and metallothioneins - platinum based drugs react preferentially with these species as they have high sulphur levels.
(3) active export via copper exporters ATP7A and 7B and glutathione S-conjugate export GS-X pump.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Once the activated aqua platinum species has entered the nucleus, preferental covalent binding to the nitrogen on position _ of ______ occurs.

A

N7 guanine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

The copper exporters ATP7A and 7B are involved with what?

A

Active export of platinum based drugs from the cytoplasm - resistance to treatment.

Also: Glutathionine S-conjugate export GS-X pump.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

The major covalen bis-adduct that is formed by the activated aqua species of platinum involves what?

A

Adjacent guanines on the same strand of DNA (the intra-strand crosslink).

A minor adduct involves binding to guanines on opposite DNA strands (the inter-strand crosslink)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Once the activated aqua platinum species has entered the nucleus, preferential covalent binding to the nitrogen on position 7 of guanine occurs. The major covalent bis-adduct that is formed involves adjacent guanines on the same strand of DNA (the intra-strand crosslink).

What is a minor adduct that is also formed?

A

Binding to guanines on opposite DNA strands: the inter-strand crosslink.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What is the main removal pathway for DNA adducts caused by platinum species?

A

Nucleotide-excision repair (NER): increased NER, especially through increased activity of the endonuclease protein ERCC1 (excision repair cross-complimenting 1) can occur in tumours, and can lead to platinum drug resistance - as the adducts are removed before apoptotic signalling pathways are triggered.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

The GS-X pump is involved with what?

A

Active export of platinum based drugs: glutathionine S-conjugate export GS-X pump.

See also:
Copper exporters ATP7A and ATP7B.

19
Q

ERCC1

A

Endonuclease protein involved in removal of the DNA adducts caused by platinum based drugs via the process of nucleotide-excision repair (NER).

Can be overexpressed in tumour cells, causing platinum drug resistance by removing adducts before the triggering of apoptotic pathways.

20
Q

NER

A

Nucleotide excision repair, ERCC1 etc.

21
Q

How can resistance to platinum drugs via increased tolerance to platinum-DNA adducts happen?

A

1) Loss of DNA mismatch repair
2) Bypassing of adducts by POLB and POLN
3) Though downregulation of apoptotic pathways.

22
Q

What are the major ongoing strategies to circumvent cisplatin and carboplatin resistance? (4)

A
  1. Increased delivery of platinum to tumours.
  2. Combination of platinum drugs with molecularly targeted agents.
  3. Using novel platinum drugs to target existing resistance mechanisms
  4. Platinum resistance modulators.
23
Q

What are examples of the ways that we can increase the delivery of platinum to tumours? (3)

A
  1. Liposomes
  2. Co-polymers
  3. Intraperitoneal administration for ovarian cancer.
24
Q

We can combine platinum drugs with molecularly targeted agents such as:

A

Bevac izu mab

Trast uzu mab

25
Q

Novel platinum drugs targeting resistance mechanisms include:

A

Oxalplatin, picoplatin.

Satraplatin

26
Q

Platinum resistance modulators such as ______ and ________ work on GSH and GST.

A

TLK286

Decitabine.

27
Q

What is avastin?

A

Monoclonal antibody (Beva izu mab) that binds with vascular endothelial growth factor (VEGF) (2), which tumour cells release to stimulate blood-vessel growth. IT prevents VEGF from interacting with VEGFR on the endothelial cells that line BVs.

28
Q

TLK286

A

Platinum resistance modulator

29
Q

Oxalplatin + picoplatin + Satraplatin

A

Novel platinum drugs targeting resistance mechanisms.

30
Q

What is the MOA of cisplatin?

A
  1. Becomes activated intracellularly by aquation of one of the two Cl leaving groups and subsequently binds to DNA forming DNA adducts.
  2. Loss of Cl is facilitated by the low chloride conc <100mM in cells.
  3. Causes mainly intrastrand bonds, 2-3% G-G interstrand links.
  4. Bends and distorts DNA, ultimately leading to apoptosis.
31
Q

What is the history of the platinum drugs?

1965

1971

1978

1989

1991

1992

1993

1997

2002

A

1965 - cisplatin, platinum electodes, no bacterial growth.

1971 - first use in patient.

1978 - first approved - testicular and bladder cancer

1989 - carboplatin approved (2nd gen)

1991 - the role of increased glutathionine levels in resistance is found

1992 - oxalplatin in clinical studies

1993 - first patient treated with the orally active satraplatin

1997 - first patient treated with picoplatin

2002 - role of copper transporter re cisplatin is discovered

32
Q

What was the design of carboplatin based off of?

A

The idea that a more stable leaving group than chloride might lower toxicity without impacting antitumour ability. True.

Carboplatin causes significantly less kidney and GI issues. However, myeleosuppression, esp thrombocytopenia is dose-limiting for carboplatin.

Cisplatin needs aggressive hydration as it is v. toxic to kidneys and GI.

33
Q

What are the resistance mechanisms to platinums? [5]

A

Less drug to DNA
Less cell death after the formation of DNA adduct formation.

  1. Cisplatin is highly polar and enters cell v. slowly.
    CTR1 is important for cisplatin influx - downregulation of CTR1 confers resistance to cisplatin treatment to cancer cells.
  2. Mopped up Cisplatin by reaction of the activated aqua species with cellular components with high sulphur levels such as many cysteine and methionine amino acids: tripeptide glutathione and metallothionens.
    - reaction of the activated cisplatin with glutathione leads to expulsion via GS-X pump.
  3. Export of platinum via ATP7A and 7B.
  4. Increased NER via ERCC1 causes the removal of cisplatinum-DNA adducts before triggering of apoptosis can occur. (NER is the major repair pathway)
  5. Increased tolerance to platinum-DNA adducts caused by:
    a) loss of mismatch repair
    b) bypassing of adducts by pol B and N
    c) downreg of apoptotic pathways as a result of other mutations
34
Q

How is cisplatin resistance tackled?

A
  1. INCREASED DELIVERY
  2. COMBINATION WITH TARGETED DRUGS
  3. RESISTANCE MODULATORS
  4. NOVEL PLATINUM DRUGS WITH LESS RESISTANCE
  5. Increased delivery: via liposomes across bilayer could bypass the issue of less CTR1. (DACH stable ligand of oxaliplatin).

Also use the EPR effect: ProLindac, exploit the increased permeability and retention of tumours.

  1. Combination with targeted drugs: Avastin, mAb for VEGF-A in renal cell carcinoma, combing platinum drug with antibody could direct the platinum just to these cells attempting angiogenesis. Also Herceptin.
  2. Resistance modulators: TLK-286 is a prodrug preferentially activated to release a nitrogen mustard alkylating agent by glutathione-metabolising enzyme, GST. This exploits the increased levelts of GSTP1 in platinum-resistant tumours and uses it to actively target these cells in tumours.

Can also combine with targeting of mTOR via RAD001.

  1. NPDWLR: oxaliplatinum, picoplatin, satraplatin.
35
Q

How does TLK-286 function as a resistance modulator?

A

TLK-286 is a prodrug preferentially activated to release a nitrogen mustard alkylating agent by glutathione-metabolising enzyme, GST. This exploits the increased levelts of GSTP1 in platinum-resistant tumours and uses it to actively target these cells in tumours.

36
Q

How can platinums be combined with mTOR inhibitors?

A

RAD001 in clinical trials

37
Q

What is cisplatin?

A

The original OG.

Nephrotoxic and GI toxic - needs lots of hydration during treatment.

38
Q

What is carboplatin?

A

The more stable leaving group than Cl leads to lower toxicity without affecting antitumour efficacy.

However thrombocytopenia is an issue, dose-limiting.

39
Q

What is oxaliplatin?

A

Accumulation less dependent on CTR1 - Mis match repair recognition proteins do not recognise oxalplatin-induced DNA adducts.

Oxaliplatin causes cumulative sensory peripheral neuropathy that is exacerbated by exposure to cold.`

40
Q

What is Satraplatin?

A

ORALLY active version of carboplatin which is also less dependent on CTR1 but has similar toxicities with reversible thrombocytopenia and neutropenia etc BUT NO neurotoxicity.

41
Q

What is Picoplatin?

A

Rationally designed for steric bulk around platinum centre to lead to a relative reduction in inactivation by thiolcontaining species like glutathione and metallothionein, in comparison to cisplatin. IV and oral.

Synergy has been demonstrated with paclitacel.
Same side effects as carboplatin of reversible thrombocytopenia and neutropenia but no neurotoxicity or nephrotoxicity.

42
Q

What is aroplatin?

A

Lead platinum liposomal drug based on the DACH stable ligand found with oxaliplatin. Modest effect phase II trials.

43
Q

What is ProLindac?

A

DACH platinum polymer combination.